First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry

被引:14
|
作者
Droz, Jean-Pierre [1 ]
Efstathiou, Eleni [2 ]
Yildirim, Asif [3 ]
Cabrera, Paula [4 ]
Kim, Choung Soo [5 ]
Horchani, Ali [6 ]
Heidenreich, Axel [7 ]
Rinck-Junior, Jose Augusto [8 ]
Hitier, Simon [9 ]
Ozen, Haluk [10 ]
机构
[1] Univ Lyon 1, Leon Berard Canc Ctr, Dept Canc, Environm Res Unit, F-69365 Lyon, France
[2] Univ Athens, Dept Med Oncol, Athens, Greece
[3] SB Goztepe Training & Res Hosp, Dept Urol, Istanbul, Turkey
[4] Inst Nacl Cancerol, Dept Urol, Mexico City, DF, Mexico
[5] Asan Med Ctr, Dept Urol, Seoul, South Korea
[6] La Rabta Hosp, Fac Med, Dept Urol, Tunis, Tunisia
[7] Univ Klinikum Aachen, Dept Urol, Aachen, Germany
[8] Hosp Canc AC Camargo, Dept Urol, Sao Paulo, Brazil
[9] Sanofi Oncol, Paris, France
[10] Hacettepe Univ, Dept Urol, Ankara, Turkey
关键词
Comorbidity; Docetaxel; Geriatric assessment; Taxoids; MITOXANTRONE PLUS PREDNISONE; DOCETAXEL; CHEMOTHERAPY; AGE; GUIDELINES; OLDER; MANAGEMENT; SURVIVAL; MEN;
D O I
10.1016/j.urolonc.2015.12.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To compare the efficacy and tolerability of taxane and nontaxane therapy in senior adults with chemonaive metastatic castration resistant prostate cancer (mCRPC), and examine the effect of patient health status on outcomes. Patients and methods: Between 2009 and 2011, 333 patients aged >= 70 years with mCRPC were enrolled in a prospective international registry. Patients were categorized as having received taxane-based or nontaxane therapy, and classified as fit, vulnerable, frail, or terminal, according to investigator judgement or International Society of Geriatric Oncology guidelines. Efficacy measures included overall survival (OS) and progression-free survival. Grade 3/4 toxicities were recorded. Predictors of OS were identified using multivariate Cox regression. Results: The proportions of fit/vulnerable/frail patients were 65%/14%/17% (International Society of Geriatric Oncology), and 39%/43%/ 17% (investigator). In single-factor analyses, taxane therapy improved OS (hazard ratio [95%CI] = 0.53 [0.30-0.93]; P = 0.027) and progression-free survival (hazard ratio [95% CI] = 0.55 [0.40-0.76]; P < 0.001) vs. nontaxane therapy. Patients with frailty also benefited from taxane therapy (adapted regimen in 52%). In multivariate analysis, taxanes improved OS even with poor prognostic factors present (P = 0.017); age was unrelated to prognosis. Taxane therapy was well tolerated; most common grade 3/4 toxicities (taxane vs. nontaxane) were fatigue (17% vs. 4%), nausea/vomiting (14% vs. 5%) and neutropenia (10% vs. 1%). Conclusions: The results of this nonrandomized, observational study suggest that first-line taxane therapy may benefit senior adults with mCRPC more than alternative therapies. Treatment decisions should not be based on chronological age. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:234.e21 / 234.e29
页数:9
相关论文
共 50 条
  • [1] Re: First-Line Treatment in Senior Adults with Metastatic Castration-Resistant Prostate Cancer: A Prospective International Registry
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2017, 197 (01): : 157 - 157
  • [2] Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
    Simon Chowdhury
    Anders Bjartell
    Nicolaas Lumen
    Pablo Maroto
    Thomas Paiss
    Francisco Gomez-Veiga
    Alison Birtle
    Gero Kramer
    Ewa Kalinka
    Dominique Spaëth
    Susan Feyerabend
    Vsevolod Matveev
    Florence Lefresne
    Martin Lukac
    Robert Wapenaar
    Luis Costa
    Targeted Oncology, 2020, 15 : 301 - 315
  • [3] Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
    Chowdhury, Simon
    Bjartell, Anders
    Lumen, Nicolaas
    Maroto, Pablo
    Paiss, Thomas
    Gomez-Veiga, Francisco
    Birtle, Alison
    Kramer, Gero
    Kalinka, Ewa
    Spaeth, Dominique
    Feyerabend, Susan
    Matveev, Vsevolod
    Lefresne, Florence
    Lukac, Martin
    Wapenaarls, Robert
    Costa, Luis
    TARGETED ONCOLOGY, 2020, 15 (03) : 301 - 315
  • [4] Taxane-based chemotherapy in senior adults with metastatic castration-resistant prostate cancer (mCRPC): A prospective international registry.
    Droz, Jean-Pierre
    Efstathiou, Eleni
    Heidenreich, Axel
    Yildirim, Asif
    Cabrera, Paula
    Kim, Choung-Soo
    Horchani, Ali
    Rinck, Jose A.
    For, Haluk Ozen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry
    Galli, Luca
    Chiuri, Vincenzo Emanuele
    Di Lorenzo, Giuseppe
    Pisconti, Salvatore
    Rossetti, Sabrina
    Sirotova, Zuzana
    Muto, Andrea
    Petrioli, Roberto
    De Tursi, Michele
    Sbrana, Andrea
    Francolini, Giulio
    Ardizzoia, Antonio
    Scavelli, Claudio
    Satta, Francesco
    Quadrini, Silvia
    Airoldi, Mario
    D'Aniello, Carmine
    Bonetti, Andrea
    Conforti, Serafino
    Aieta, Michele
    Beccaglia, Patrizia
    Maestri, Antonio
    Fratino, Lucia
    TUMORI JOURNAL, 2023, 109 (02): : 224 - 232
  • [6] Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] EFFICACY AND TOLERABILITY OF TAXANE-BASED CHEMOTHERAPY IN SENIOR ADULTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): A PROSPECTIVE INTERNATIONAL REGISTRY
    Droz, J.
    Efstathiou, E.
    Heidenreich, A.
    Yildirim, A.
    Cabrera, P.
    Kim, C.
    Horchani, A.
    Ozen, H.
    Rinck, J. A., Jr.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 308
  • [8] Management of metastatic castration-resistant prostate cancer after first-line docetaxel
    Harrington, J. A.
    Jones, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2133 - 2142
  • [9] Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
    Caffo, Orazio
    Lo Re, Giovanni
    Sava, Teodoro
    Buti, Sebastiano
    Sacco, Cosimo
    Basso, Umberto
    Zustovich, Fable
    Lodde, Michele
    Perin, Alessandra
    Facchini, Gaetano
    Veccia, Antonello
    Maines, Francesca
    Barile, Carmen
    Fratino, Lucia
    Gernone, Angela
    De Vivo, Rocco
    Pappagallo, Giovanni L.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2015, 11 (06) : 965 - 973
  • [10] Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment
    Thurin, Nicolas H.
    Rouyer, Magali
    Jove, Jeremy
    Gross-Goupil, Marine
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    de Pouvourville, Gerard
    Pierres, Marie
    Capone, Camille
    Lamarque, Stephanie
    Bignon, Emmanuelle
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 114 - 114